Cancer Chemotherapy and Pharmacology 2009-12-01

Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.

Holly J Meany, Katherine E Warren, Elizabeth Fox, Diane E Cole, Alberta A Aikin, Frank M Balis

Index: Cancer Chemother. Pharmacol. 65(1) , 137-42, (2009)

Full Text: HTML

Abstract

Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide.Temozolomide was administered orally, daily for 5 days starting at 28 mg/m(2) per day with escalations to 40, 55, 75 and 100 mg/m(2) per day with O(6)BG intravenously daily for 5 days at doses of 60, 90 or 120 mg/m(2) per day. Plasma samples were drawn over 48 h after the day 5 dose. Temozolomide was quantified with a validated HPLC/tandem mass spectroscopic assay.Temozolomide was rapidly absorbed (mean T (max), 2.1 h). The mean apparent clearance (CL/F) (96 mL/min/m(2)) was similar to the CL/F for temozolomide alone and was not age- or gender-dependent. There was minimal inter-patient variability.The enhanced hematologic toxicity resulting from combining O(6)BG with temozolomide does not appear to be the result of a pharmacokinetic interaction between the agents.

Related Compounds

  • O6-Benzylguanine

Related Articles:

Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.

2014-07-01

[Cancer Biol. Ther. 15(7) , 938-50, (2014)]

Formation and repair of pyridyloxobutyl DNA adducts and their relationship to tumor yield in A/J mice.

2012-10-15

[Chem. Res. Toxicol. 25(10) , 2167-78, (2012)]

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.

2015-01-01

[Mol. Cancer Ther. 14(1) , 111-9, (2015)]

4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.

2011-11-10

[J. Med. Chem. 54(21) , 7720-8, (2011)]

Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

2012-05-01

[Arch. Dermatol. 148(5) , 613-20, (2012)]

More Articles...